Dialysis Centers in European Union 2026: Industry Statistics & Trends

The dialysis centers industry in the European Union provides life-sustaining kidney replacement therapies, primarily hemodialysis and peritoneal dialysis, to patients experiencing end-stage kidney disease (ESKD). The industry is expanding its deployment of outpatient, home-based, and digital monitoring solutions across member states to accommodate structural demographic shifts. According to official epidemiological data published in the ERA Registry Annual Report 2022, the overall incidence rate of patients initiating kidney replacement therapy stood at 152 per million population in 2022 (ERA Registry). At the initiation of this therapy, the vast majority of patients depend on clinical facil

Industry snapshot

Key public data points

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Dialysis Centers in European Union industry cover?

The dialysis centers industry encompasses dedicated medical facilities and specialized outpatient clinics that administer filtration therapies to individuals with severe renal failure. These facilities manage the extraction of metabolic waste products and excess fluid from patients whose kidneys can no longer perform these functions naturally. The core operational scope comprises center-based hemodialysis, automated or continuous ambulatory peritoneal dialysis support, and associated laboratory, nutritional, and patient training services.

• •Centers operate within the institutional boundaries of medical care systems, managing specialized machinery to clean patient blood.
• •Under the European statistical standard, these activities are classified within the broader health services framework under NACE Rev. 2 group 86.10 for hospital activities and 86.22 for specialist medical practice activities.
• •The scope also spans training and equipment logistics required to facilitate home-based hemodialysis and peritoneal dialysis modalities.

Who operates in the industry and how is it structured?

The European dialysis landscape is a hybrid ecosystem consisting of public hospitals, non-profit community clinics, and large-scale commercial networks. The exact operational mix varies significantly by EU member state due to localized healthcare funding and reimbursement mechanisms. While public entities anchor the acute and initial therapy segments, specialized multinational corporations play an instrumental role in managing standalone outpatient networks across the continent.

• •Public health insurance funds and national health services serve as the primary payers, determining fixed reimbursement tariffs per treatment cycle.
• •Operational models lean toward public-private partnerships in several Western and Central European countries to optimize capital expenditure.
• •The market demonstrates a moderate concentration, with large specialized providers acquiring independent regional clinics to generate procurement efficiencies.

What drives demand in the industry?

The underlying demand for dialysis services across the European Union is consistently propelled by long-term demographic and epidemiological trends. An aging European population inherently leads to a higher prevalence of chronic kidney disease, as renal function naturally declines with age. Furthermore, systemic lifestyle factors have triggered a multi-year rise in secondary medical conditions that directly damage kidney architecture.

• •In incident European patients starting kidney replacement therapy, 54 percent were aged 65 years or older in 2022 (ERA Registry).
• •Diabetes mellitus represents the leading primary renal disease, accounting for 22 percent of all new incident dialysis cases in 2022 (ERA Registry).
• •Prevalent patients on ongoing kidney replacement therapy reached a density of 1,074 per million population on December 31, 2022 (ERA Registry).

Who are the notable companies in the industry?

The competitive environment in the European Union features heavily consolidated healthcare groups and vertically integrated medical device firms that control both manufacturing lines and clinic networks. These multinational operators achieve significant scale by pairing their clinical care divisions with proprietary dialyzer and solution production assets. Competition is centered around service quality, patient outcomes, geographic footprint, and compliance with stringent public tender specifications.

• •Fresenius SE & Co. KGaA, through its healthcare segments including Fresenius Helios, commands a vast network of outpatient medical care centers and hospitals across Germany and Spain.
• •B. Braun Melsungen AG operates extensive renal care networks globally and throughout the European Union via its B. Braun Avitum division.
• •Diaverum AB, a prominent Sweden-headquartered multinational provider, delivers specialized renal care services across numerous European clinics.
• •Baxter International Inc. acts as a critical institutional counterpart in the EU market, supplying essential peritoneal dialysis and hemodialysis solutions from regional manufacturing sites.

What are the recent trends and outlook?

Modern operational strategies among EU dialysis centers focus extensively on green dialysis initiatives and the integration of digital health applications. Providers are modernizing clinical infrastructure to mitigate the high consumption of water and electricity typical of standard hemodialysis procedures. Additionally, there is a clear institutional push toward expanding home therapies and remote monitoring protocols to improve patient autonomy and lower center overheads.

• •Of the total prevalent patient cohort requiring kidney replacement therapy, 56 percent were treated via facility-based hemodialysis at the close of 2022 (ERA Registry).
• •Peritoneal dialysis was utilized by a smaller slice of 5 percent of the prevalent patient population on December 31, 2022 (ERA Registry).
• •Remote patient management tools are increasingly linked to clinical registries to track real-time compliance and minimize emergency readmissions.

How is the industry regulated?

Dialysis facilities within the European Union are bound by dual layers of oversight, encompassing strict pan-European medical directives and national healthcare quality guidelines. Regulations control everything from the structural design of water treatment systems to the validation of individual single-use medical components. Strict reporting regimes require data submission to centralized clinical registries to monitor multi-regional treatment standards.

• •Medical hardware, consumables, and dialyzers must strictly conform to the European Union Medical Device Regulation (MDR 2017/745).
• •Manufacturing plants and solution suppliers are subject to severe quality audits by the European Medicines Agency (EMA) to prevent endotoxin and bacterial contaminations.
• •Clinical performance and epidemiological data are tracked dynamically by regional bodies cooperating with the European Renal Association (ERA) Registry.

Government, statistical and trade sources used for this Claight analysis.

• ERA Registry Annual Report 2022 ·
• European Medicines Agency (EMA) ·
• Eurostat NACE Rev. 2 Classification System ·
• Fresenius SE & Co. KGaA Annual Report 2024